We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
Cap. Flow
+$284M
Cap. Flow %
244.1%
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122

Top Buys

1
MDVN
MEDIVATION, INC.
MDVN
+$4.59M
2
BIIB icon
Biogen
BIIB
+$3.56M
3
CALM icon
Cal-Maine
CALM
+$2.79M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.48M
5
AAPL icon
Apple
AAPL
+$2.33M

Top Sells

1
BAX icon
Baxter International
BAX
+$4.11M
2
GILD icon
Gilead Sciences
GILD
+$2M
3
IBM icon
IBM
IBM
+$1.48M
4
CMG icon
Chipotle Mexican Grill
CMG
+$930K
5
EXPE icon
Expedia Group
EXPE
+$914K

Sector Composition

1 Healthcare 41.4%
2 Technology 6.27%
3 Consumer Staples 4.14%
4 Consumer Discretionary 2.26%
5 Materials 1.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBUX icon
401
CALL
Starbucks
SBUX
$120B
– –
-20,000
Closed -$49K
SBUX icon
402
Starbucks
SBUX
$120B
– –
-3,581
Closed -$214K
SBUX icon
403
PUT
Starbucks
SBUX
$120B
– –
-74,800
Closed -$30K
THS
404
CALL
DELISTED
Treehouse Foods
THS
– –
-17,100
Closed -$178K
THS
405
DELISTED
Treehouse Foods
THS
– –
-3,937
Closed -$342K
VYX icon
406
PUT
NCR Voyix
VYX
$1.13B
– –
-16,300
Closed -$8K
WOLF icon
407
CALL
Wolfspeed
WOLF
$1.55B
– –
-5,800
Closed -$7K
WOLF icon
408
Wolfspeed
WOLF
$1.55B
– –
-1,400
Closed -$41K
WOLF icon
409
PUT
Wolfspeed
WOLF
$1.55B
– –
-5,800
Closed -$18K
XBI icon
410
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-15,000
Closed -$775K
XBI icon
411
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-30,000
Closed -$25K
BIG
412
CALL
DELISTED
Big Lots, Inc.
BIG
– –
-21,200
Closed -$10K
BIG
413
PUT
DELISTED
Big Lots, Inc.
BIG
– –
-8,800
Closed -$1K
SIOX
414
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-2,500
Closed -$10K
AERI
415
DELISTED
Aerie Pharmaceuticals
AERI
– –
-12,614
Closed -$153K
AERI
416
PUT
DELISTED
Aerie Pharmaceuticals
AERI
– –
-15,000
Closed -$43K
GBT
417
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-26,711
Closed -$424K
RDUS
418
CALL
DELISTED
Radius Health, Inc.
RDUS
– –
-29,600
Closed -$8K
MXIM
419
CALL
DELISTED
Maxim Integrated Products
MXIM
– –
-39,800
Closed -$89K
ALXN
420
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-10,000
Closed -$9K
FPRX
421
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-15,312
Closed -$622K
FPRX
422
PUT
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-34,300
Closed -$174K
TIF
423
CALL
DELISTED
Tiffany & Co.
TIF
– –
-26,300
Closed -$62K
TIF
424
PUT
DELISTED
Tiffany & Co.
TIF
– –
-46,300
Closed -$35K
MNK
425
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-30,000
Closed -$40K
15 16
17
18 19

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q2 2016 Portfolio in Review

As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.

  • FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
  • FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
  • FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
  • FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
  • FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
  • FT Options opened 171 new positions and closed 122 in Q2 2016.
  • FT Options's portfolio value rose 22% quarter-over-quarter to $116M.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.